BRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months

Reuters04-03

April 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:

EYLEA HD® (AFLIBERCEPT) APPROVED BY FDA AS FIRST AND ONLY INJECTABLE ANTI-VEGF WITH DOSING INTERVALS UP TO 5 MONTHS FOR WET AGE-RELATED MACULAR DEGENERATION (WAMD) AND DIABETIC MACULAR EDEMA (DME)
REGENERON PHARMACEUTICALS INC - FDA TARGET ACTION DATE IN APRIL 2026 FOR EYLEA HD PREFILLED SYRINGE

Source text: ID:nGNX7ty14s

Further company coverage: REGN.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624531685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-03 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624531685","market":"nz","top_or_hot":-1,"title":"BRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months </title></head><body><p><span>April 2 (Reuters)</span><span> - </span>Regeneron Pharmaceuticals Inc <span>REGN.O</span>:</p><ul><li><p>EYLEA HD® (AFLIBERCEPT) APPROVED BY FDA AS FIRST AND ONLY INJECTABLE ANTI-VEGF WITH DOSING INTERVALS UP TO 5 MONTHS FOR WET AGE-RELATED MACULAR DEGENERATION (WAMD) AND DIABETIC MACULAR EDEMA (DME)</p></li><li><p>REGENERON PHARMACEUTICALS INC - FDA TARGET ACTION DATE IN APRIL 2026 FOR EYLEA HD PREFILLED SYRINGE</p></li></ul><p>Source text: <span>ID:nGNX7ty14s</span></p><p>Further company coverage: <span>REGN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-03 00:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months </title></head><body><p><span>April 2 (Reuters)</span><span> - </span>Regeneron Pharmaceuticals Inc <span>REGN.O</span>:</p><ul><li><p>EYLEA HD® (AFLIBERCEPT) APPROVED BY FDA AS FIRST AND ONLY INJECTABLE ANTI-VEGF WITH DOSING INTERVALS UP TO 5 MONTHS FOR WET AGE-RELATED MACULAR DEGENERATION (WAMD) AND DIABETIC MACULAR EDEMA (DME)</p></li><li><p>REGENERON PHARMACEUTICALS INC - FDA TARGET ACTION DATE IN APRIL 2026 FOR EYLEA HD PREFILLED SYRINGE</p></li></ul><p>Source text: <span>ID:nGNX7ty14s</span></p><p>Further company coverage: <span>REGN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2362541273.HKD","symbol_name":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUA4D6F0T:1","article_id":"2624531685","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624531685","pubTimestamp":1775147760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months April 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:EYLEA HD (AFLIBERCEPT) APPROVED BY F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","REGN":"再生元制药公司","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"简介-Eylea HD获FDA批准为首个也是唯一一个给药间隔长达5个月的可注射抗Vegf药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"BRIEF-Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months April 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:EYLEA HD® (AFLIBERCEPT) APPROVED BY FDA AS FIRST AND ONLY INJECTABLE ANTI-VEGF WITH DOSING INTERVALS UP TO 5 MONTHS FOR WET AGE-RELATED MACULAR DEGENERATION (WAMD) AND DIABETIC MACULAR EDEMA (DME)REGENERON PHARMACEUTICALS INC - FDA TARGET ACTION DATE IN APRIL 2026 FOR EYLEA HD PREFILLED SYRINGESource text: ID:nGNX7ty14sFurther company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624531685","isCrawlerRequest":true}